Teva Pharmaceutival Industries has made a hostile takeover bid of around $149 million for U.S. drug developer company NuPathe, plus additional milestone payments for the company’s migraine treatment Zecuity, NuPathe said Wednesday.
- Israel-based Teva needs strategy reset with new CEO
- Teva fears profit plunge as patent on multiple sclerosis drug runs out
Teva is offering $3.65 a share for the company — a 13% premium over its closing price on Nasdaq Tuesday of $3.26 per share — plus up to $3.15 per share, or $98 million, if sales goals for Zecurity are met.
U.S. drug developer Endo Health Solutions offered in December to buy NuPathe for about $105 million in cash, or $2.85 per share, plus as much as $3.15 a share in milestone payments.
After the announcement of Teva’s offer, Nupathe’s share price rocketed up 37%, to $4.41 in premarket trading.
NuPathe specializes in the treatment of diseases of the central nervous system, including Parkinson’s disease, schizophrenia and bipolar disorder, in addition to migraine.
In related news, South Korean newspaper Maeil reported that Teva was among parties in talks to buy the Korean biotech firm Celltrion. The other parties mentioned in the report were Roche and AstraZeneca. Celltrion is trading on the Korea Exchange at a market value of $4.6 billion.